HSM Helius Medical Technologies Inc

Helius Medical Technologies, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Helius Medical Technologies, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEWTOWN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the H.C. Wainwright Annual Global LifeSciences Conference, which is being held virtually from September 13th-15th. Management’s presentation will be available on-demand beginning on Monday, September 13th at 7:00 a.m. Eastern Time. Management will participate in investor meetings throughout the duration of the conference.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform including the Portable Neuromodulation Stimulator (PoNS™). For more information, visit .

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS™) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the Australia (“AUS”) and is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:

Westwicke on behalf of Helius Medical Technologies, Inc.

Jack Powell, Vice President

 



EN
07/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Helius Medical Technologies Inc

 PRESS RELEASE

Solana Company (NASDAQ: HSDT) Becomes First Digital Asset Treasury to ...

Solana Company (NASDAQ: HSDT) Becomes First Digital Asset Treasury to Enable Borrowing Against Natively Staked SOL in Qualified Custody Solana Company (HSDT), Anchorage Digital, and Kamino collaborate to bring institutional capital to Solana's high-performance DeFi ecosystem through a first-of-its-kind tri-party custody model Institutions earn staking rewards while accessing on-chain liquidity—24/7 automated collateral management enables real-time borrowing operations without sacrificing custody, compliance, or operational control Scalable model designed to provide a blueprint for other t...

 PRESS RELEASE

Solana Company Reports Third Quarter 2025 Financial Results

Solana Company Reports Third Quarter 2025 Financial Results NEWTOWN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter ended September 30, 2025. Third Quarter and Recent Business Updates Closed partnership with Pantera Capital and Summer Capital of over $500 Million in funding in cash and stablecoins to launch SOL treasury strategyIssued cash-ex...

 PRESS RELEASE

Solana Company to Release Third Quarter Operating Results on November ...

Solana Company to Release Third Quarter Operating Results on November 18, 2025 NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its third quarter operating results on Tuesday, November 18, 2025, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Tuesday, Novembe...

 PRESS RELEASE

Solana Company Announces Intent to Tokenize HSDT Shares on Superstate’...

Solana Company Announces Intent to Tokenize HSDT Shares on Superstate’s Opening Bell NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced its plans to tokenize shares of its HSDT fund on ’s Opening Bell platform. The initiative marks a major step forward in the Company’s strategy to modernize access to capital markets through regulated, onchain infrastructure. Upon launch, sharehol...

 PRESS RELEASE

Solana Company (NASDAQ: HSDT) Releases Investor Update

Solana Company (NASDAQ: HSDT) Releases Investor Update NEWTOWN, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that its Board of Directors has approved a stock repurchase program to acquire up to $100 million of the company's outstanding common stock. The new stock repurchase program, which is open-ended, allows the company to repurchase its shares from time to time in the open market ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch